Avricore Health Reports Steep Revenue Decline and Going Concern Warning Amid Major Customer Loss
summarizeSummary
The company's financial results for the nine months ended September 30, 2025, show a drastic 85% year-over-year revenue decrease and a shift to a comprehensive loss of $916,042. This severe deterioration is primarily due to the conclusion of its agreement with Shoppers Drug Mart, a major customer. Management explicitly stated a "material uncertainty" about the company's ability to continue as a going concern, highlighting its historical operating losses and negative cash flows. While the company outlines a strategy to focus on the UK market and redeploy existing devices, the immediate financial challenges and the going concern warning present significant risks to investors.
check_boxKey Events
-
Going Concern Warning Issued
Management disclosed a material uncertainty regarding the company's ability to continue as a going concern, citing historical operating losses and negative cash flows.
-
Significant Revenue Decline
Revenue for the nine months ended September 30, 2025, plummeted 85% year-over-year to $500,433, primarily due to the expiration of a major customer agreement.
-
Shift to Comprehensive Loss
The company reported a comprehensive loss of $916,042 for the nine-month period, a significant reversal from income in the prior year.
-
Cash Flow Deterioration
Net cash used in operating activities resulted in a $600,111 decrease in cash and cash equivalents for the nine-month period.
auto_awesomeAnalysis
The company's financial results for the nine months ended September 30, 2025, show a drastic 85% year-over-year revenue decrease and a shift to a comprehensive loss of $916,042. This severe deterioration is primarily due to the conclusion of its agreement with Shoppers Drug Mart, a major customer. Management explicitly stated a "material uncertainty" about the company's ability to continue as a going concern, highlighting its historical operating losses and negative cash flows. While the company outlines a strategy to focus on the UK market and redeploy existing devices, the immediate financial challenges and the going concern warning present significant risks to investors.
في وقت هذا الإيداع، كان AVCRF يتداول عند ٠٫٠٤ US$ في OTC ضمن قطاع Life Sciences، مع قيمة سوقية تقارب ٣٫٦ مليون US$. تراوح نطاق التداول خلال 52 أسبوعًا بين ٠٫٠١ US$ و٠٫٢٥ US$. تم تقييم هذا الإيداع على أنه ذو معنويات سوقية سلبية وبدرجة أهمية ٩ من 10.